期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 22, 期 2, 页码 339-343出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2015.10.013
关键词
Umbilical cord blood transplantation; Second allogeneic transplantation; Donor source
资金
- National Institutes of Health [R24 HL74445, K23 HL077446, K12 CA076930, RC2HL101844, P50 HL110787]
- medac GmbH
- Fondazione Internazionale di Ricerca in Medicina Sperimentale, Torino, Italy - Provincia di Benevento
- Damon Runyon Cancer Research Foundation [35-07]
For patients with disease relapse or graft failure after allogeneic hematopoietic cell transplantation (HCT), there are few treatment options and survival rates are exceedingly low. Because of the unacceptably high risk of transplantation-related mortality, second allogeneic HCTs are often not considered. Herein, we report the outcomes of 23 patients (median age, 33 years) undergoing a second allogeneic transplantation with unrelated cord blood donor grafts between 2006 and 2013. Indications for second HCT were relapse (n = 19), graft failure (n = 3), and donor-derived myelodysplastic syndrome (n = 1). Ten patients received reduced-intensity conditioning and 13 patients received either myeloablative (MAC) or middle-intensity (MIDI) conditioning. Twenty patients received a double cord blood transplantation. All patients engrafted at a median of 22 days (range, day 6 to 49). Death before day 100 occurred in 5 patients. Overall disease-free survival (DFS), treatment-related mortality, and relapse at 2 years were 31%, 33%, and 35%, respectively. Two-year DFS in the 13 patients receiving MAC or MIDI conditioning was slightly higher at 46%. Our results demonstrate that second allogeneic HCT using cord blood as the graft source should be considered in patients who have relapsed or experience graft failure after an allogeneic HO'. (C) 2016 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据